Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...
Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...
Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...
Detailed price information for Aclaris Therapts (ACRS-Q) from The Globe and Mail including charting and trades.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Genesis Healthcare, Inc. (Genesis) today announced that its chapter 11 plan became effective, following the closing of the sale of substantially all of its operating assets to 101 W.
Travelers (TRV) has an average rating of hold and mean price target of $378.79, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks ...
Stock market news for October 23, 2026. Press releases, financial news, and business developments from public companies with ...
Travere Therapeutics, Inc. präsentierte neue Biomarkerdaten aus der Phase-3-PROTECT-Studie, die darauf hindeuten, dass ...
Travere Therapeutics presentó hallazgos de biomarcadores del estudio de Fase 3 PROTECT que sugieren que FILSPARI podría ...
아스트라제네카 (AstraZeneca)의 보체 억제제 '울토미리스 (Ultomiris, 성분명 라불리주맙·ravulizumab)'가 미국 식품의약국 (FDA)으로부터 원발성 면역글로불린A 신증 (IgAN) 성인 환자의 단백뇨 ...
En ny strålende trav- og galopphelg er i emning. Det er klart for en ny runde med Super Saturday kommende lørdag med 55 millioner i samlet premiepott. Først ut er det Jägersro med V85 og her er det ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results